Consistent with this observation, multiple SIK3 inhibitors (dasatinib and YKL-06-062) significantly decreased granzyme B release by PBMCs at concentrations that did not affect the viability of PBMCs (Supplementary Fig. 2l), suggesting that SIK3 inhibition has a cancer cell-independent anti-immunogenic effect. This evidence concerns the gene SIK3 and cancer.